Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 3,272
Out of 4,412 analysts
6
Total ratings
n/a
Success rate
-42.99%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Reiterates: Neutral | n/a | $2.52 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $2.08 | +332.69% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $7.69 | +121.07% | 1 | Mar 22, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.71 | - | 2 | Mar 14, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $111.62 | - | 1 | Apr 26, 2023 |
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.52
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $2.08
Upside: +332.69%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $7.69
Upside: +121.07%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.71
Upside: -
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $111.62
Upside: -